Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.43 |
| ▸ | ADH1B | P00325 | 2/20 | 0.39 |
| ▸ | ADH1C | P00326 | 2/20 | 0.39 |
| ▸ | ADH1A | P07327 | 2/20 | 0.39 |
| ▸ | ADH7 | P40394 | 2/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1793429 | 1.00 | TSHR (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL28603348 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL10627520 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL11148458 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL1794187 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL1795018 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL15477622 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL1794183 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL1795020 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B | |
| SCHEMBL1794716 | 0.97 | EPHX1 (0.48) | TSHRALDH1A1EPHX1DNM1ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0398842-A1 | Hydrazide derivatives | CIBA-GEIGY AG (CH) | 1990-11-22 | — | — | EP | claimed |
| CN-116789932-A | Recyclable polyurethane elastomer containing multiple hydrogen bonds and obtained through chain extension of aldehyde groups and preparation method of recyclable polyurethane elastomer | 山东奥卓新材料有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-113831681-B | Low-release polyformaldehyde and preparation method thereof | 重庆云天化天聚新材料有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-111163638-A | Pesticidal compositions and methods | 美国陶氏益农公司 | 2020-05-15 | — | — | CN | disclosed |
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8822459-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8618122-B2 | Compound having acidic group which may be protected, and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-6846933-B1 | Antimycobacterial compounds and method for making the same | THE BOARD OF TRUSTEES OF WELLESLEY COLLEGE (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2002043668-A2 | ANTIMYCOBACTERIAL COMPOUNDS AND METHOD FOR MAKING THE SAME | WELLESLEY COLLEGE (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0398842-A1 | Hydrazide derivatives | CIBA-GEIGY AG (CH) | 1990-11-22 | — | — | EP | disclosed |
| US-4252958-A | ACETONE COMPOUND, AMMONIA DONER, HYDRAZINE HYDROHALIDE CATALYST | ARGUS CHEMICAL CORPORATION (US) | 1981-02-24 | — | — | US | disclosed |
| US-3941808-A | POLYAMIDE AMINE SALTS OF A STYRENE-MALEIC ANHYDRIDE COPOLYMER | ATLANTIC RICHFIELD COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | TSHR 1566/4885ALDH1A1 1623/4885EPHX1 513/4885 |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | TSHR 935/4885ALDH1A1 793/4885EPHX1 889/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | TSHR 2187/4885ALDH1A1 334/4885EPHX1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.